A randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type non-small-cell lung cancer.
about
Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer.
P2860
A randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type non-small-cell lung cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A randomized phase II study of ...... pe non-small-cell lung cancer.
@en
type
label
A randomized phase II study of ...... pe non-small-cell lung cancer.
@en
prefLabel
A randomized phase II study of ...... pe non-small-cell lung cancer.
@en
P2093
P2860
P1433
P1476
A randomized phase II study of ...... pe non-small-cell lung cancer.
@en
P2093
Shouhui Zhu
Shuo Zhang
Yong Zhang
Yonghua Yu
Yongsheng Gao
P2860
P304
P356
10.3109/07357907.2015.1024318
P577
2015-05-07T00:00:00Z